Maywufa Co (TPE:1731) EBIT: NT$237 Mil (TTM As of Dec. 2025)


TPE:1731 Maywufa Co Ltd TPE:1731
86 GF Score
Price NT$20.65
GF Value NT$26.79
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Maywufa Co EBIT?

Maywufa Co TPE:1731 86 EBIT is NT$237 Mil as of Dec. 2025. GuruFocus rates TPE:1731 with a GF Score™ of 86/100 and a GF Value™ of NT$26.79 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Maywufa Co's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2025 was NT$47 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$237 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Maywufa Co's annualized ROC % for the quarter that ended in Dec. 2025 was 5.75%. Maywufa Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 13.37%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Maywufa Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 8.56%.


Maywufa Co  (TPE:1731) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Maywufa Co's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=163.132 * ( 1 - 21.72% )/( (2230.34 + 2209.486)/ 2 )
=127.6997296/2219.913
=5.75 %

where

Invested Capital(Q: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3106.917 - 356.395 - ( 520.182 - max(0, 380.458 - 1110.732+520.182))
=2230.34

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3237.44 - 407.892 - ( 620.062 - max(0, 433.201 - 1209.501+620.062))
=2209.486

Note: The Operating Income data used here is four times the quarterly (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Maywufa Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=189.476/( ( (1251.076 + max(197.655, 0)) + (1241.814 + max(143.401, 0)) )/ 2 )
=189.476/( ( 1448.731 + 1385.215 )/ 2 )
=189.476/1416.973
=13.37 %

where Working Capital is:

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(276.64 + 295.469 + 3.5339999999999) - (356.395 + 0 + 21.593)
=197.655

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(272.945 + 298.331 + 2.9100000000001) - (407.892 + 0 + 22.893)
=143.401

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Maywufa Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=236.846/2766.399
=8.56 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Maywufa Co EBIT Related Terms


Maywufa Co EBIT Historical Data

* Premium members only.

The historical data trend for Maywufa Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Maywufa Co EBIT Chart

Maywufa Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 217.09 210.91 210.34 221.23 236.85

Maywufa Co Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 39.59 67.08 69.18 53.22 47.37

TPE:1731 vs ZTS, UTHR: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Maywufa Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Maywufa Co EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Maywufa Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Maywufa Co's EV-to-EBIT falls into.


TPE:1731
86GF Score
Maywufa Co Ltd TPE:1731
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Maywufa Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$237 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of NT$237 Mil mean?
Maywufa Co (TPE:1731) has a EBIT of NT$237 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Maywufa Co.
Is Maywufa Co's EBIT too high?
Maywufa Co's current EBIT is NT$237 Mil. Overall, Maywufa Co has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Maywufa Co's EBIT compare to ZTS and UTHR?
Maywufa Co's EBIT of NT$237 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Maywufa Co. Maywufa Co's current EBIT is NT$237 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Maywufa Co stock overvalued right now?
Based on GuruFocus' analysis, Maywufa Co (TPE:1731) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$26.79, compared to a current price of NT$20.65 — trading 22.9% below its estimated fair value. The current EBIT is NT$237 Mil. Maywufa Co's overall GF Score™ is 86/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Maywufa Co (TPE:1731), the current EBIT is NT$237 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Maywufa Co (TPE:1731) Overvalued in 2026?

Based on GuruFocus' analysis, Maywufa Co stock appears to be undervalued. The current stock price of NT$20.65 is trading 22.9% below its estimated GF Value™ of NT$26.79. GuruFocus considers Maywufa Co to be Modestly Undervalued.

Key valuation signals for TPE:1731:

  • EBIT: NT$237 Mil
  • GF Value™: NT$26.79 vs. price of NT$20.65 (22.9% below fair value)
  • GF Score™: 86/100 with 5 warning signs

No single metric tells the full story. See the TPE:1731 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Maywufa Co Business Description

Address No. 167, Fu-Shing N. Road, 5th Floor, Taipei, TWN, 105
Maywufa Co Ltd operates as a drug manufacturer. The company is engaged in manufacturing of hair and skin care products. The company has two reportable segments segments: Management Department, Consumer Business Unit, and Pharmaceutical Business Unit. It derives maximum revenue from Pharmaceutical Business Unit.
86GF Score

Get the complete analysis for TPE:1731

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$20.65
Price
NT$26.79
GF Value